Acalabrutinib Maleate
Brand name: Calquence
Rank #41 of 500 drugs by total cost
$457.0M
Total Cost
31,890
Total Claims
$457.0M
Total Cost
1,328
Prescribers
$14K
Cost per Claim
490
Beneficiaries
32,065
30-Day Fills
$344K
Avg Cost/Provider
24
Avg Claims/Provider
About Acalabrutinib Maleate
Acalabrutinib Maleate (sold as Calquence) was prescribed 31,890 times by 1,328 Medicare Part D providers in 2023, costing the program $457.0M. At $14K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 38 | Fluticasone/Vilanterol (Breo Ellipta) | $493.0M | 909,837 |
| 39 | Tiotropium Bromide (Spiriva Handihaler) | $478.1M | 673,800 |
| 40 | Evolocumab (Repatha Sureclick) | $460.5M | 528,560 |
| 41 | Acalabrutinib Maleate (Calquence) | $457.0M | 31,890 |
| 42 | Atorvastatin Calcium (Atorvastatin Calcium) | $444.6M | 30,263,929 |
| 43 | Osimertinib Mesylate (Tagrisso) | $436.5M | 25,273 |
| 44 | Levothyroxine Sodium (Levothyroxine Sodium) | $435.3M | 20,209,418 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology